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Abstract
Background: Arthritogenic alphaviruses, including Chikungunya virus (CHIKV), are responsible for acute fever and arthralgia,
but can also lead to chronic symptoms. In 2006, a Chikungunya outbreak occurred in La Re´union Island, during which we
constituted a prospective cohort of viremic patients (n = 180) and defined the clinical and biological features of acute
infection. Individuals were followed as part of a longitudinal study to investigate in details the long-term outcome of
Chikungunya.
Methodology/Principal Findings: Patients were submitted to clinical investigations 4, 6, 14 and 36 months after
presentation with acute CHIKV infection. At 36 months, 22 patients with arthralgia and 20 patients without arthralgia were
randomly selected from the cohort and consented for blood sampling. During the 3 years following acute infection, 60% of
patients had experienced symptoms of arthralgia, with most reporting episodic relapse and recovery periods. Long-term
arthralgias were typically polyarthralgia (70%), that were usually symmetrical (90%) and highly incapacitating (77%). They
were often associated with local swelling (63%), asthenia (77%) or depression (56%). The age over 35 years and the presence
of arthralgia 4 months after the disease onset are risk factors of long-term arthralgia. Patients with long-term arthralgia did
not display biological markers typically found in autoimmune or rheumatoid diseases. These data helped define the features
of CHIKV-associated chronic arthralgia and permitted an estimation of the economic burden associated with arthralgia.
Conclusions/Significance: This study demonstrates that chronic arthralgia is a frequent complication of acute Chikungunya
disease and suggests that it results from a local rather than systemic inflammation.
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Introduction
Chikungunya virus (CHIKV) is an arthropod-borne virus that
belongs to the Alphavirus genus. Chikungunya disease is character-
ized by polyarthralgia, sometimes associated with rash. The
articular symptoms, often debilitating, usually resolve within
weeks, but have been reported to last for months, even though
the natural history of this infection has not been precisely studied
in prospective studies [1,2,3].
In 2005, CHIKV emerged in islands of Indian Ocean including
La Re´union, a French overseas department, and approximately one
third of the inhabitants (i.e.,300,000) was infected at the end of the
outbreak in 2006 [4,5]. Compared to earlier outbreaks, this episode
occurred in a highly medicalized area. Moreover previously
unreported severe forms of Chikungunya were observed, such as
encephalopathy [6,7], and mother-to-child CHIKV transmission
was demonstrated, leading to severe neonatal CHIKV infection [5].
In the wake of this outbreak, CHIKV also re-emerged in India with
over 1 million cases [8,9]. In 2007, CHIKV emerged for the first
time in Europe, causing an outbreak in Italy [10].
We have described the clinical and biological features of acute
CHIKV infection in a prospective cohort of patients with positive
blood CHIKV RT-PCR [11]. It included all patients referred to
the Emergency Department in Saint-Pierre de la Re´union with
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febrile arthralgia between March and May 2006. As little is known
about long-term outcome of CHIKV infection, we conducted a
prospective longitudinal study to describe in details the specific
clinical and biological features of chronic arthralgia, as well as
clinical signs associated to this pathology. We evaluated the
consequences of long-term arthralgia on patients’ daily and social
life, looked for risk factors associated with them and estimated
their economic impact.
Materials and Methods
Ethics & STROBE statement
Ethical clearance was obtained from the «Comite´ de Protection
des Personnes Sud-Ouest et Outre-Mer III» of Saint-Pierre, La
Re´union, Paris (CCP 2008/65, nu 2008-A00999-46). CHIK-
IMMUNOPATH received approval from the ethical committee
for studies with human subjects (CPP) of Bordeaux and the
National Commission for Informatics and Liberty (CNIL). Written
informed consent was obtained from patients included in the
CHIK-IMMUNOPATH study. The study respects the STROBE
statement (supporting information S1).
Patients
We studied a cohort of patients (n = 180) enrolled for febrile
arthralgia to the Emergency Department of the Groupe
Hospitalier Sud Re´union between March 2005 and May 2006
[11]. Patients were interviewed by telephone 4, 6, 14 and 36
months (M4, M6, M14 and M36) after the viremic phase, using
the same questionnaire as that used at day 0 (D0) (supporting
information S2). At M36 after the acute phase, all patients who
agreed to participate to a complementary study (CHIK-IMMU-
NOPATH) and who were arthralgic were interviewed and
underwent clinical examination. Among them, 22 patients with
arthralgia (ART+) and 20 patients without persisting arthralgia
(ART2) were randomly selected from the cohort. They signed a
written consent and a blood sample was collected.
Laboratory tests performed at M36
Blood cell count was performed and viremia was tested by qRT-
PCR [12]. Both serum anti-CHIKV IgG and IgM specific
antibodies were screened. An enzyme-linked immunosorbent assay
(ELISA) was performed with CHIKV antigen [12]. The avidity of
anti-CHIKV IgG was tested by ELISA in the presence or absence
of urea 8 M [13]. Geometric Mean Antibody Titer (GMAT) was
calculated as previously described [14].
Plasmatic protein electrophoresis was performed and C-reactive
protein (CRP) concentration was measured. The presence of anti-
nuclear, anti-dsDNA, anti-endomysium autoantibodies, anti-cyclic
citrullinated peptide antibody (ACCP) and cryoglobulinemia were
investigated. Samples were transported at 37uC to research
cryoglobulins. Sera were sent to Myriad RBM (Austin,Texas)
and analyzed by Luminex using the inflammation MAP. Assays
are run according to CLIA guidelines and in all cases, .100 beads
per analyte were measured with CV ,10% for values that are
above the limit of quantification for the given assay.
Statistical analysis
For each time point, the proportion of patients with mono-
arthralgia (1 site), oligoarthralgia (2–3 sites) or polyarthralgia (4
sites or more) were compared using a Chi-2 test.
A logistic regression model was used to identify factors associated
with long-term arthralgia, defined as presence of arthralgia at M14.
We studied factors at D0, including demographic factors (gender
and age), biological markers, hospitalization and comorbidities, and
factors measured at M4 (arthralgia, treatment, and quality of life).
All factors associated with long-term arthralgia with a p-value,0.15
in univariate analysis were entered in the multivariate model. A
step-by-step backward procedure was then used to identify factors
significantly associated with long-term arthralgia. A sensitivity
analysis was also conducted, following the same procedure, defining
long-term persistence of arthralgia as the presence of arthralgia at
M36. To address the lost of follow up at M36, we looked for
parameters that differentiate the patients who were lost between
M14 and M36 and these who were followed.
Statistical analyses were performed using the STATA software
(Stata Corporation, College Station, Texas, USA); all significance
tests were two-sided and p-values,0.05 were considered significant.
Luminex data were mined using the Omniwiz software (Biowisdom)
and Mann-Whitney analysis is reported. False discovery rate (FDR or
q-values) were calculated as correction for multiple analyte testing.
To characterize the spatiotemporal evolution of arthralgia, we
considered different types of arthralgia. For a given site at a given
time point, arthralgia was defined either as a ‘‘persistent symptom’’
if the affected site was the same as that reported during the previous
time point, as ‘‘a relapse of an the acute symptom’’ if the site affected
was the same as that at the acute phase, or as ‘‘a new symptom’’ if
this site was not affected at the acute phase, or as a ‘‘migrating
symptom’’ if the arthralgia was localized at a site distinct from that
previously reported. For a given patient, these categories were not
mutually exclusive. For modeling migratory arthralgia, we divided
joints into three groups: upper limb joints (hand, wrist, elbow), mid
body joints, (shoulder, spine, hip) and lower limb joints (foot, ankle,
knee), and considered two migratory probabilities for migration to
sites within to the same group (e.g., hand to wrist) or to a different
group (e.g., hand to foot) (Supporting information S3 and Table S1).
Results
Characteristics of long-term arthralgia in CHIKV-infected
patients
At M4, M6, M14 and M36 after their inclusion as acute
CHIKV-infected patients, all patients were interviewed using a
questionnaire to monitor persistence of arthralgia, other clinical
signs and treatments. The number of patients that participated is
Author Summary
Chikungunya virus (CHIKV) is transmitted to human by
mosquitoes. It is a re-emerging virus that has a risk to
spread globally, given the expanding dissemination of its
mosquito vectors. Chikungunya disease is characterized by
acute transient febrile arthralgic illness, but can also lead
to chronic incapacitating arthralgia. We have conducted a
prospective longitudinal study to investigate in details
long-term outcome of CHIKV infection. We found that 60%
of patients experienced arthralgia 36 months after the
onset of acute disease. Arthralgia affected most often
multiple sites and were usually incapacitating. In addition
to arthralgia, many patients suffered from myalgia and
cutaneous lesions and several cognitive dysfunctions. We
also showed that age over 35 years and the presence of
arthralgia 4 months after the onset of disease are risk
factors for long-term arthralgia. Patients with long-term
arthralgia did not display biological markers typically
found in autoimmune or rheumatoid diseases. This study
demonstrates that chronic arthralgia is a frequent compli-
cation of acute Chikungunya disease and suggests that it
results from a local rather than systemic inflammation.
Chikungunya Virus Chronic Arthralgia
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provided in Figure 1. There is an important lost of follow up
between M14 and M36 however we did not identify a bias
associated with it. Among the 180 patients, 76 patients were
followed at all time points of the study.
The percentage of patients suffering from long-term arthralgia
decreased after CHIKV acute infection and stabilized around
60% (Figure 2A). Of note, all patients suffered from arthralgia at
D0. Among them, only 5 on 180 (2.8%) suffered from joint pain
prior to CHIKV infection.
Most patients had intermittent arthralgia, with recovery and
relapse. For each time point, 25 to 40% of patients complained of
permanent arthralgia. Among the 76 patients that could be
followed at each time point, 45% had arthralgia at all time, 24%
experienced partial recovery at M4, M6 or M14 then relapses, and
31% fully recovered from acute symptoms. Among patients who
experienced chronic symptoms at M36, 43.5% reported arthralgia
triggered by a change in ambient temperature, 8% by physical
effort. At M36, arthralgia caused stiffness in 75.5% of patients with
symptoms, and 67.7% of the patients reported a need of morning
stretching (time of 32 minutes, standard deviation (SD) 37 min-
utes, range 5–180 minutes).
We monitored arthralgia in 9 anatomical sites (Figure 2B).
Arthralgia in upper limbs mostly affected fingers and wrists, while
lower limbs arthralgia mostly affected knees and ankles. At each
time point, these locations remain significantly the most affected
(Mac Nemar test for matched pairs of subjects). Importantly,
arthralgia were typically symmetrical (90%).
We then investigated whether the number of arthralgic sites
diminished in patients still suffering from arthralgia among the 76
patients followed at all time points. The number of arthralgia sites
Figure 1. Diagram of the clinical study. ‘‘unable’’: patients who were reached but unable to answer to the questionnaire, ‘‘lost’’: patient lost of
follow up until the end of the study, ‘‘temporally lost’’: not reached at a specific timepoint, ‘‘death’’: dead patients.
doi:10.1371/journal.pntd.0002137.g001
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decreased until M14, with only 30% of patients suffering from
polyarthralgia (number of arthralgia sites .2) (Figure 2C). Despite an
increase of arthralgic sites at M36, there is an overall significant decrease
of the number of painful joints during the study period (p,0.01).
We attempted to model the spatiotemporal evolution of arthralgia,
as defined in the Materials and Methods section. We found that
‘‘persistent’’ symptoms had the strongest effect, as its probability of
occurrence was three times higher than a ‘‘new’’ symptom (Figure 2D).
The probability of relapse of an ‘‘acute’’ symptom was twice the
appearance of a ‘‘new’’ symptom. Finally, ‘‘migratory’’ symptoms
tended to be intra-group as compared to inter-group migrations.
Other clinical signs associated with CHIKV chronic
disease and their consequences
Patients with arthralgia at M36 showed other clinical symptoms,
including local swelling, cutaneous symptoms, myalgia and
osteoligamentaous pain (Table 1). Local swelling localized to
affected joints for 63% of patients. Moreover, sleep, memory or
Figure 2. Evolution and characterization of arthralgia in CHIKV patients. (A) Percentage of patients with arthralgia among participating
patients, (B) localization of arthralgia among patients with arthralgia, (C) number of arthralgia sites among the 76 patients answering at every time
point and having arthralgia, (D) complete model presenting the probability for one joint to be painful depending on its previous state.
doi:10.1371/journal.pntd.0002137.g002
Chikungunya Virus Chronic Arthralgia
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Table 1. Clinical signs and treatment in arthralgic and non-arthralgic patients 36 months after the acute phase.
Patients with arthralgia (n=62) Patients w/o arthralgia (n =33) Chi-2 test1
Clinical signs
Local swelling 39 (62.9%) 0 (0%) ***
Osteo-ligamentous pain 22 (35.5%) 0 (0%) ***
Myalgia 24 (38.7%) 0 (0%) ***
Cutaneous lesion 31 (50.0%) 5 (15.1%) ***
Asthenia 48 (77.4%) 7 (21.2%) ***
Sleeping disorder 35 (56.4%) 3 (9.1%) ***
Dysgeusia 11 (17.7%) 3 (9.1%) NS
Depression 31 (50.0%) 2 (6%) ***
Memory disorder 27 (43.5%) 2 (6%) ***
Concentration disorder 24 (38.7%) 2 (6%) ***
Treatment
Followed by a general practioner 50 (80.6%) 1 (3%) ***
Treatment 51 (82.2%) 0 (0%) ***
Continous treatment 25 (49%) 0 (0%) ***
Paracetamol 45 (72.5%) 0 (0%) ***
Morphinic 0 (0%) 0 (0%)
Non-steroidal anti-inflammatory drugs 12 (23.5%) 0 (0%) **
Corticosteroids 3 (5.9%) 0 (0%) NS
1ns: Non significant.
**p,0.01.
***p,0.001.
doi:10.1371/journal.pntd.0002137.t001
Table 2. Impact of arthralgia on daily life for patients at M36.
Arthralgic patients (n=62) Non arthralagic patients (n=33) Chi-2 test1
Impact on quality of life
rising from a chair 39 (48.4%) 0 (0%) ***
walking 34 (54.8%) 0 (0%) ***
picking up an object 34 (54.8%) 0 (0%) ***
opening a bottle 33 (53.2%) 0 (0%) ***
drinking glass 26 (41.9%) 0 (0%) ***
to wash oneself 23 (37.1%) 0 (0%) ***
At least one of these disabilities 48 (77.4%) 0 (0%) ***
Impact on working life
With activity 15 (24.2%) 17 (51.5%)
No impact 3 (20%) 16 (94.1%) ***
Physical impact 12 (80%) 1 (5.9%)
low impact 7 (46.7%) 1 (5.9%)
moderate impact 3 (20%) 0 (0%)
high impact 2 (13.3%) 0 (0%)
Impact on leisure-time
No impact 13 (39.4%) 31 (93.9%)
Physical impact 49 (79%) 2 (6.1%) ***
low impact 8 (24.2%) 1 (3%)
moderate impact 18 (54.5%) 0 (0%)
high impact 23 (69.7%) 1 (3%)
1**p,0.01. ***p,0.001.
doi:10.1371/journal.pntd.0002137.t002
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concentration disorders and asthenia or depression are signifi-
cantly associated with arthralgic patients.
The proportion of patients with arthralgia who attended a
physician or received a treatment significantly increased between
M4 and M36 (p = 0.01) (data not shown), and reached 80%
(Table 1). Similarly, the number of patients receiving a treatment
increased and these treatments are statistically associated with the
arthralgic status of the patient (p,0.001).
Arthralgia in patients at M36 were highly incapacitating for
daily life tasks, professional life and spare-time activities (Table 2).
Identification of risk factors for developing long-term
CHIKV-associated arthralgia
To identify risk factors associated with long-term arthralgia, we
performed univariate and multivariate statistical analyses at M14,
as the participation was higher than at M36 (Table 3). Gender was
Table 3. Identification of risk factors for persistence of arthralgia 14 months after CHIKV acute disease (univariate analysis).
Patients at M14 N
Patients with arthralgia N
(%) Odd Ratio (95% CI1) p
Gender
Male 73 41 (56.2%) 0.78 (0.40–1.51) 0.46
Female 74 46 (62.2%) 1
Age (years)
#35 30 9 (30.0%) 0.18 (0.05–0.57) 0.005
36–50 28 19 (67.9%) 0.87 (0.26–2.84)
51–60 24 17 (70.8%) 1
61–70 20 15 (75.0%) 1.24 (0.32–4.73)
.70 45 27 (60.0%) 0.62 (0.21–1.79)
Hospitalization at D0
No 101 61 (60.4) 1 0.66
Yes 46 26 (56.5) 0.85 (0.42–1.73)
Viral quantification at D0 (copies/
mL)
#100.000 70 39 (55.7) 1 0.41
.100.000 77 48 (62.3) 1.32 (0.68–2.54)
CRP at D0 (unit)
,10 20 7 (35.0) 1 0.02
.10 126 79 (62.7) 3.12 (1.16–8.38)
Missing 1 1 (100.0) No estimable
Diabetes at D0
No 109 58 (53.2) 1 0.01
Yes 38 29 (76.3) 2.83 (1.23–6.54)
Arthralgia at M4
No 26 5 (19.2) 0.10 (0.04–0.30) ,0.001
Yes 99 69 (60.7) 1
Missing 22 13 (59.1) 0.63 (0.24–1.62)
Arthralgia at M4
No 26 5 (19.2) 0.25 (0.08–0.78) ,0.001
Yes. intermittent 43 21 (48.8) 1
Yes. permanent 56 48 (85.7) 6.28 (2.41–16.38)
Missing 22 13 (59.1) 1.51 (0.53–4.28)
Memory disorder at M4
No 87 41 (47.1) 1 ,0.001
Yes 38 33 (86.8) 7.40 (2.64–20.75)
Missing 22 13 (59.1) 1.62 (0.63–4.18)
Concentration disorder at M4
No 94 45 (47.9) 1 ,0.001
Yes 31 29 (93.6) 15.79 (3.56–69.97)
Missing 22 13 (59.1) 1.57 (0.61–4.03)
1confidence interval.
doi:10.1371/journal.pntd.0002137.t003
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Table 4. Analytes titrated in arthralgic and non arthralgic patients 36 months after the acute phase.
Arthalgia (n =20 patients) No Arthalgia (n=22 patients) Statistic
ATTRIBUTE Units LOD DET 25% MED 75% DET 25% MED 75% M-W PV M-W FDR
IP-10 pg/mL 116 18 170 214 376 20 126 207 379 0.537 0.606
Alpha-2-Macroglobulin A2Macro mg/mL 0.472 18 0.6 0.7 0.9 21 0.7 0.8 1.1 0.194 0.434
Alpha-1-Antitrypsin AAT mg/mL 1.33 20 1.9 2.1 2.6 22 1.8 2.0 2.1 0.305 0.606
Beta-2-Microglobulin B2M ug/mL 0.914 20 1.1 1.4 1.9 22 1.2 1.3 1.6 0.481 0.606
Brain-Derived Neurotrophic Factor
BDNF
ng/mL 4.7 20 12 17 24 22 14 18 21 0.940 0.966
Complement C3 C3 mg/mL 0.93 20 1.4 1.5 1.8 22 1.0 1.2 1.5 0.029 0.056
C-Reactive Protein CRP ug/mL 0.063 20 1.5 2.8 5.8 22 0.5 1.3 2.4 0.035 0.056
Eotaxin-1 pg/mL 70.8 20 165 195 290 22 154 238 329 0.705 0.920
Factor VII ng/mL 142 20 443 529 632 22 324 383 561 0.020 0.056
Fibrinogen ug/mL 0.93 20 1.6 1.9 2.4 22 1.4 2.0 2.4 0.950 0.966
Ferritin FRTN ng/mL 14.7 20 34 112 156 22 68 159 273 0.034 0.056
Granulocyte-Macrophage Colony-
Stimulating Factor
pg/mL 0 0 0.0 0.0 0.0 0 0.0 0.0 0.0 NA NA
Haptoglobin mg/mL 0.007 20 1.0 1.6 2.1 21 0.6 0.9 1.8 0.194 0.434
Intercellular Adhesion Molecule 1
ICAM-1
ng/mL 32.1 20 88 98 119 22 87 107 121 0.801 0.920
Interferon gamma IFN-gamma pg/mL 0.9 6 0.9 0.9 0.9 2 0.9 0.9 1.0 0.038 0.056
Interleukin-1 alpha IL-1 alpha pg/mL 1.51 2 1.4 1.4 3.1 10 1.4 1.4 1.4 0.007 0.010
Interleukin-1 beta IL-1 beta pg/mL 2.68 0 2.4 2.4 2.4 2 2.4 2.4 2.4 0.091 0.112
Interleukin-10 IL-10 pg/mL 1.55 17 1.6 2.2 2.8 18 1.6 2.2 2.6 0.808 0.920
Interleukin-12 Subunit p40 IL-12p40 ng/mL 0 0 0.0 0.0 0.0 0 0.0 0.0 0.0 NA NA
Interleukin-12 Subunit p70 IL-12p70 pg/mL 29.3 0 29 29 29 3 29 29 29 0.051 0.056
Interleukin-15 IL-15 ng/mL 0.2 5 0.2 0.2 0.4 11 0.2 0.2 0.2 0.021 0.056
Interleukin-17 IL-17 pg/mL 0.9 9 0.9 0.9 1.5 11 0.9 0.9 1.5 0.838 0.920
Interleukin-18 IL-18 pg/mL 61.3 20 117 135 235 22 130 153 189 0.811 0.920
Interleukin-1 receptor antagonist
IL-1ra
pg/mL 50.2 15 87 113 154 22 49 87 129 0.090 0.112
Interleukin-2 IL-2 pg/mL 2.8 0 2.8 2.8 2.8 2 2.8 2.8 2.8 0.573 0.606
Interleukin-23 IL-23 ng/mL 0.4 8 0.4 0.4 0.7 8 0.4 0.4 0.7 0.787 0.920
Interleukin-3 IL-3 pg/mL 5.1 1 5.1 5.1 5.1 0.0 5.1 5.1 5.1 NA NA
Interleukin-4 IL-4 pg/mL 2.6 1 2.6 2.6 2.6 5 2.6 2.6 2.6 0.111 0.112
Interleukin-5 IL-5 pg/mL 3.8 11 3.8 4.8 6.8 16 3.4 3.8 5.1 0.168 0.406
Interleukin-6 IL-6 pg/mL 5.8 1 5.8 5.8 5.8 0 5.8 5.8 5.8 0.133 0.352
Interleukin-7 IL-7 pg/mL 5 4 5.0 5.0 5.0 1 5.0 5.0 5.0 0.112 0.112
Interleukin-8 IL-8 pg/mL 2.8 19 9 17 46 20 9 11 24 0.650 0.897
Monocyte Chemotactic Protein 1
MCP-1
pg/mL 33.7 20 105 170 216 22 129 150 172 0.435 0.606
Macrophage Inflammatory Protein-1
alpha MIP-1 alpha
pg/mL 10.6 15 11 16 46 16 11 27 36 0.869 0.933
Macrophage Inflammatory Protein-1
beta MIP-1 beta
pg/mL 112 20 194 284 431 22 242 269 328 0.950 0.966
Matrix Metalloproteinase-2 MMP-2 ng/mL 0 0 0.0 0.0 0.0 0 0.0 0.0 0.0 NA NA
Matrix Metalloproteinase-3 MMP-3 ng/mL 2.31 20 2.9 5.7 8.8 22 5.5 6.9 10.3 0.162 0.406
Matrix Metalloproteinase-9 MMP-9 ng/mL 1.3 12 1.2 1.3 1.3 15 1.2 1.3 1.3 0.305 0.606
T-Cell-Specific Protein RANTES
RANTES
ng/mL 3.81 20 7 16 21 22 9 17 23 0.345 0.606
Stem Cell Factor SCF pg/mL 60.4 20 155 192 229 22 140 167 219 0.239 0.514
Tissue Inhibitor of
Metalloproteinases 1 TIMP-1
ng/mL 68.7 20 120 132 169 22 126 144 177 0.623 0.897
Tumor Necrosis Factor alpha TNF-
alpha
pg/mL 1.33 20 2.0 2.2 2.7 21 1.8 2.2 2.7 0.643 0.897
Chikungunya Virus Chronic Arthralgia
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not associated with long-term arthralgia, age less than 35 years was
protective. Risk of arthralgia was not associated with indicators of
the disease severity during the acute phase (viral load, duration of
hospitalization or number of sites of arthralgia at D0) [11],
however it was weakly associated with C-reactive protein (CRP)
level at D0. Diabetes was the only comorbidity found to be a risk
factor for long-term arthralgia. Interestingly, arthralgia at M14
was strongly associated with arthralgia at M4, and even more if
arthralgia was permanent at M4. Memory and concentration
disorders at M4 were also identified as risk factors for developing
long-term arthralgia. Arthralgia, memory disorders and concen-
tration disorders at M4 were the only risk factors significantly and
independently associated with long-term arthralgia. When long-
term arthralgia was assessed at M36, results were very similar.
Arthralgia status, systemic inflammation and
autoimmunity markers
At M36, 22 patients with arthralgia (ART+) and 20 patients
without arthralgia (ART2) were randomly selected from the
cohort to participate to the CHIK IMMUNOPATH study. Its
aim was to titrate anti-CHIKV antibodies and identify a serum
inflammatory or autoimmune signature associated with the
arthralgia phenotype.
All patients were negative for CHIKV RT-PCR, and exhibited
anti-CHIKV IgGs in serum, while a minority (9.5%) harbored
measurable levels of anti-CHIKV IgM. The activity of CHIKV
IgG (GMAT) was significantly higher in ART+ patients (30) than
in ART2 patients (20), but antibody avidity was comparable in
both groups (mean 6SD: 31,6620,4 in ART + patients and
33,7619,8 in ART2 patients). Although lymphopenia is a
defining feature of acute CHIKV disease [11], it was a rare
finding at M36 (data not shown). Plasma protein levels measured
by electrophoresis and CRP concentration were within normal
ranges. However, CRP levels were significantly higher in the
ART+ group than in the ART2 group (mean 6SD:
3.3563.00 mg/ml and 1.8562.49 mg/ml, respectively; p = 0.04).
We used Luminex xMAP technology to assay analytes in the
serum of patients. Most analytes were undetectable in both groups
of patients (Table 4). Five inflammation markers were significantly
elevated in ART+ patients: factor VII, C3 complement component,
IL1a, IL15 and CRP (Figure 3). Ferritin level was significantly lower
in ART+ patients than in ART2 patients. These markers did not
allow for the identification of a subgroup within the ART+ group,
nor did they correlate one with another. No autoimmune marker
and no anti-DNA antibody in the serum of ART+ patients were
detected, although anti-nuclear antibodies were detected at low
level in four ART+ patients. Three patients had elevated anti-
nuclear antibodies, one in the ART+ group and two in the ART-
group.
As it has been reported that CHIKV could evolve into
rheumatoid arthritis [15], we screened for cyclic citrullinated
protein antibodies. We also assayed for cryoglobulinemia and anti-
endomysium IgA antibodies. All patient were found to be negative.
Estimation of the economic impact of CHIKV long-term
arthralgia
We estimated the annual economic burden of long-term
arthralgia by taking into account the cost of medical visits,
therapeutic treatment and the cost for lost work time due to injury
or pain (using the population of La Re´union Island as a reference)
(Table S2). We found that arthralgia secondary to the CHIKV
outbreak in La Re´union in 2005-06 has resulted so far in an
estimated total cost of up to 34 millions euros per year. This
corresponds to 250J per year and per patient with long-term
arthralgia. However, it should be noted that this sum might be
overestimated due to the bias in our cohort selection, as our cohort
is likely composed of the most severely affected patients who were
referred to the hospital during the acute phase.
Discussion
Our study is the first prospective cohort study on CHIKV long-
term arthralgia that is based on the follow-up of patients who
presented with acute CHIKV infection as the inclusion criterion.
This study is also the first to define the evolution of CHIKV-
induced arthralgia, mapping the frequency and location of
arthralgic sites during a three year time period. We have also
investigated the impact of CHIKV-chronic arthralgia on daily life
of patients, identified clinical signs associated with arthralgia, and
analyze biologic markers. Moreover we have evaluated associated
risk factors and estimated the economic burden of this disease.
Table 4. Cont.
Arthalgia (n =20 patients) No Arthalgia (n=22 patients) Statistic
ATTRIBUTE Units LOD DET 25% MED 75% DET 25% MED 75% M-W PV M-W FDR
Tumor Necrosis Factor beta
TNF-beta
pg/mL 12.1 1 12 12 12 1 12.1 12.1 12.1 0.612 0.897
Tumor Necrosis Factor
Receptor-Like 2 TNFR2
ng/mL 2.51 20 3 4 8 22 3.3 4.0 5.2 0.364 0.606
Vascular Cell Adhesion Molecule-1
VCAM-1
ng/mL 323 20 460 595 707 22 490 539 640 0.606 0.606
Vitamin D-Binding Protein VDBP ug/mL 114 20 158 273 372 22 237 259 303 0.762 0.920
Vascular Endothelial Growth
Factor VEGF
pg/mL 288 20 458 628 763 22 492 579 786 0.811 0.920
von Willebrand Factor vWF ug/mL 13.7 20 21 28 35 22 20 26 34 0.762 0.920
DET: number of patients with detectable value within the group.
MED: 25%; 75%:median and interquartile.
LOD: lowest limit of detection.
M-W PV: Mann Whithney P value.
M-W FDR Mann Whitney with False Discovery Rate Correction.
doi:10.1371/journal.pntd.0002137.t004
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Together, these data allow us to define the features of CHIKV-
induced chronic arthralgia (Table 5), as compared to other viral
arthritis [16], and to establish a detailed understanding of the
public health problem resulting from CHIKV-chronic arthralgia.
Our data reveal that more than 60% of CHIKV-infected
patients suffer from arthralgia, 36 months after acute infection.
This high percentage of patients with long-term symptoms was
also reported by other studies of Italian cohorts and French
cohorts of La Re´union Island or metropolitan France
[17,18,19,20,21] but is dramatically higher than documented in
India and Senegal [1,22,23,24,25]. While this discrepancy may
result from particular features of the CHIKV strain responsible for
the La Re´union outbreak, data from Italy following the 2007
outbreak resulted from a CHIKV strain more closely related to the
viral strain present in India [10], with more than 60% of CHIKV
patients in Italy having reported myalgia, asthenia or arthralgia
12–13 months after the acute disease [20]. Alternatively, reported
differences may be a result of different genetic backgrounds of
these populations. As joint pain is considered a subjective
symptom, it might also reflect a difference in pain threshold of
patients or reporting from physicians, thus reflecting differences in
health care practices.
Long-term CHIKV-associated arthralgia were mainly symmet-
rical, involving more than 2 different joints. Hand, wrist, ankle and
knee were found to be the most affected, consistent with other
studies [17,18]. Moreover, 60–80% of patients had relapsing
arthralgia, while 20–40% had unremitting arthralgia. While some
patients reported ‘‘migrating’’ arthralgia, most disease symptoms
mapped to joints that were most painful during acute Chikungu-
nya disease. Thus, symptoms at the chronic phase may be
indirectly associated to virus replication at the time of acute
infection [26,27,28].
In addition to arthralgia, many patients suffered from myalgia
and cutaneous lesions and several cognitive dysfunctions. Although
study patients did not display neurological symptoms at the acute
phase of disease, we cannot exclude that cognitive dysfunctions
result from CHIKV spread in the CNS, as it has been reported
that CHIKV disseminates to the CNS in humans and in animal
Figure 3. Distinctive markers in serum of patients with arthralgia (ART+ in black) versus patients without arthralgia (ART2, in
white) at M36. SD: standard deviation, results of Mann Whitney test are shown. * p,0.05, q = 0.056.
doi:10.1371/journal.pntd.0002137.g003
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models [12,26,27,29]. Similar to other studies, chronic arthralgia
are considered incapacitating for daily life tasks and impacted
professional activities and quality of life [20,21]. Beside this impact
on patient, the economic burden of this long-term pathology is also
very significant, independently of the cost of the acute disease [30].
The longitudinal design of our study enabled us to identify risk
factors for development of long-term arthralgia. Individuals over
the age of 35 years or with diabetes were more likely to suffer from
chronic arthralgia. The age has been reported to be a risk factor
with some cohorts [21,31,32], but not in others [18,33]. None of
our available parameters to measure the severity of acute disease
were associated with long-term arthralgia. This may be explained
by differences in the way to measure disease severity in other
studies [18]. Importantly, we show that the presence and intensity
of arthralgia at M4 after the onset of the acute disease is a good
predictor of long-term arthralgia.
Our study did not identify positive markers for autoimmune or
rheumatoid arthritis. Additionally, we failed to identify systemic
biomarkers associated with the arthralgic phenotype. Nevertheless,
a slightly more elevated inflammatory status is found in a subset of
arthralgic patients who have detectable serum level of IL1a, IL15
and slight elevation in Factor VII, C3 and CRP. This signature
differs from that observed at the onset of the infection, when
circulating virus is detectable and type I interferon, IP10, MCP1,
ISG15 are highly elevated [34,35,36]. Others have identified IL6
and GM-CSF or IL12 as being specifically associated with long-
term arthralgia [32,33]. However, these studies were performed
much earlier in the chronic phase (2–3 months and one year after
disease onset).
Our study shows that anti-CHIKV antibody titers were more
elevated in ART+ patients than in ART- patients. This is in
agreement with a recent study [37]. This higher level of antibodies
could be associated with a more severe acute infection [37].
However, in our study, the level of antibody at M36 did not
correlate with acute disease severity. Alternatively, this could
reflect a persisting antigenic stimulation in ART+ patients (see
below). Interestingly, it has been reported that viremia level at the
acute phase correlates with a faster appearance of neutralizing
antibodies and a better recovery 2–3 months after the acute phase
[38].
Similarly to CHIKV, other so called ‘‘arthritogenic’’ alpha-
viruses, notably Ross River virus (RRV), are known to cause
acute as well as chronic arthralgia [39]. Our data indicates that
chronic symptoms are linked to the initial local joint inflamma-
tion and are not associated with markers of systemic inflamma-
tion or autoimmunity. A local inflammation of the joint could be
maintained by the local persistence or delayed clearance of viral
antigens. This is consistent with report of Hoarau et al. [32] who
detected persistent CHIKV antigens within the synovial fluid of a
patient suffering from chronic arthralgia. Moreover, experimental
studies in CHIKV infected animal indicate that the joint is the
most highly infected tissue, making it plausible that incomplete
viral antigen clearance in this anatomical site may account for the
long-term symptoms [26]. RRV has been shown to persist in vitro
in mouse macrophages, and a model of RRV chronic arthritis
suggests that viral persistence may account for chronic disease
[40]. RRV and CHIKV have been shown to be weakly tropic for
macrophages in vitro [41,42] but the presence of antibodies
dramatically increased RRV entry into macrophage [42]. Further
studies will be required to assess the role of macrophages, as well
the role of persistent infection and antibodies in chronic arthritis
caused by CHIKV.
In sum, this study furthers our understanding of the patho-
physiology of CHIKV chronic arthralgia, a prerequisite for the
development of efficient therapeutic strategies and for assessing the
burden of disease inflicted upon populations affected by epidemic
Chikungunya disease.
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Table 5. Features of patients with chronic CHIKV-associated
arthralgia.
Age .35
Sex ratio (M/F) 1/1
Number of sites oligo or polyarthralgia
Sites upper limbs : fingers. wrist
lower limbs : knees. ankles
Type symmetrical
permanent or not
migratory
highly incapacitating
morning stiffness duration average:
<30 minutes
General sign fever no fever
Other clinical signs edema
cutaneous lesion
myalgia
sleep and memory disorders
Laboratory tests CRP normal
ACCP normal
antinuclear normal
anti CHIKV IgGs positive
Risk factor diabetes
doi:10.1371/journal.pntd.0002137.t005
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